Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

ClinicalTrials.gov ID: NCT04684394

Public ClinicalTrials.gov record NCT04684394. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 9, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Multiple-Dose Study in Neovascular Age-related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct to Standard of Care Aflibercept Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to investigate the safety and tolerability of GEM103 IVT injection + standard of care vs. sham + standard of care.

Study identification

NCT ID
NCT04684394
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gemini Therapeutics, Inc.
Industry
Enrollment
50 participants

Conditions and interventions

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 28, 2020
Primary completion
Jan 9, 2022
Completion
Feb 17, 2022
Last update posted
Oct 30, 2022

2020 – 2022

United States locations

U.S. sites
23
U.S. states
13
U.S. cities
22
Facility City State ZIP Site status
Gemini Clinical Trial Site 16 Phoenix Arizona 85021
Gemini Clinical Trial Site 11 Campbell California 95008
Gemini Clinical Trial Site 9 Encino California 91436
Gemini Clinical Trial Site 17 Huntington Beach California 92647
Gemini Clinical Trial Site 12 Pasadena California 91107
Gemini Clinical Trial Site 5 Miami Florida 33143
Gemini Clinical Trial Site 7 Pinellas Park Florida 33782
Gemini Clinical Trial Site 20 Sarasota Florida 34239
Gemini Clinical Trial Site 8 Stuart Florida 34994
Gemini Clinical Trial Site 18 Winter Haven Florida 33880
Gemini Clinical Trial Site 19 Indianapolis Indiana 46290
Gemini Clinical Trial Site 4 Hagerstown Maryland 21740
Gemini Clinical Trial Site 23 Worcester Massachusetts 01605
Gemini Clinical Trial Site 22 Royal Oak Michigan 48073
Gemini Clinical Trial Site 1 Reno Nevada 89502
Gemini Clinical Trial Site 2 Asheville North Carolina 28803
Gemini Clinical Trial Site 15 Charlotte North Carolina 28210
Gemini Clinical Trial Site 6 Cincinnati Ohio 45219
Gemini Clinical Trial Site 10 Eugene Oregon 97401
Gemini Clinical Trial Site 13 Beaufort South Carolina 29902
Gemini Clinical Trial Site 3 Dallas Texas 75231
Gemini Clinical Trial Site 21 San Antonio Texas 78240
Gemini Clinical Trial Site 14 San Antonio Texas 78247

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04684394, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 30, 2022 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04684394 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →